Sekar Kathiresan
2021
In 2021, Sekar Kathiresan earned a total compensation of $5.6M as Chief Executive Officer at Verve Therapeutics, a 131% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $455,400 |
|---|---|
| Option Awards | $4,585,975 |
| Salary | $519,000 |
| Other | $12,183 |
| Total | $5,572,558 |
Kathiresan received $4.6M in option awards, accounting for 82% of the total pay in 2021.
Kathiresan also received $455.4K in non-equity incentive plan, $519K in salary and $12.2K in other compensation.
Rankings
In 2021, Sekar Kathiresan's compensation ranked 2,293rd out of 12,406 executives tracked by ExecPay. In other words, Kathiresan earned more than 81.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,293 out of 12,406 | 82nd |
Division Manufacturing | 894 out of 5,494 | 84th |
Major group Chemicals And Allied Products | 342 out of 2,369 | 86th |
Industry group Drugs | 296 out of 2,090 | 86th |
Industry Pharmaceutical Preparations | 190 out of 1,537 | 88th |
Source: SEC filing on April 29, 2022.
Kathiresan's colleagues
We found two more compensation records of executives who worked with Sekar Kathiresan at Verve Therapeutics in 2021.